Jan Krijt

Dr. Jan Krijt


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JFJana Frýdlová
Jana Frýdlová
PPPetr Prikryl
Petr Prikryl
Jaroslav TruksaJaroslav Truksa
Jaroslav Truksa
LFLucas L. Falke
Lucas L. Falke
XDXin Du
Xin Du
JKJan Krijt
Jan Krijt
Matriptase-2 (TMPRSS6) is an important negative regulator of hepcidin expression; however, the effects of iron overload or accelerated erythropoiesis on liver TMPRSS6 protein content in vivo are largely unknown. We determined TMPRSS6 protein content in plasma membrane-enriched fractions of liver homogenates by immunoblotting, using a commercial antibody raised against the catalytic domain of TMPRSS6. Plasma membrane-enriched fractions were obtained by centrifugation at 3000 g and washing. TMPRSS6 was detected in the 3000 g fraction as a 120 kDa full-length protein in both mice and rats. Feeding of iron-deficient diet as well as erythropoietin treatment increased TMPRSS6 protein content in rats and mice by a posttranscriptional mechanism; the increase in TMPRSS6 protein by erythropoietin was also observed in Bmp6-mutant mice. Administration of high doses of iron to mice (200, 350 and 700 mg/kg) decreased TMPRSS6 protein content. Hemojuvelin was detected in the plasma membrane-enriched fractions of control animals as a full length protein of approximately 52 kDa; in iron deficient animals, the full length protein was partially cleaved at the N-terminus, resulting in an additional weak band of approximately 47 kDa. In livers from hemojuvelin-mutant mice, TMPRSS6 protein content was strongly decreased, suggesting that intact hemojuvelin is necessary for stable TMPRSS6 expression in the membrane. Overall, the results demonstrate posttranscriptional regulation of liver TMPRSS6 protein by iron status and erythropoietin administration, and provide support for the interaction of TMPRSS6 and hemojuvelin proteins in vivo.

Verified
Journal Article
Open access
PDF file
BBBetty Berezovsky
Betty Berezovsky
JFJana Frýdlová
Jana Frýdlová
IGIuliia Gurieva
Iuliia Gurieva
DRDaniel W. Rogalsky
Daniel W. Rogalsky
MVMartin Vokurka
Martin Vokurka
JKJan Krijt
Jan Krijt
The purpose of the study was to investigate the expression of ferroportin protein following treatments that affect systemic hepcidin. Administration of erythropoietin to C57BL/6J mice decreased systemic hepcidin expression; it also increased heart ferroportin protein content, determined by immunoblot in the membrane fraction, to approximately 200% of control values. This increase in heart ferroportin protein is very probably caused by a decrease in systemic hepcidin expression, in accordance with the classical regulation of ferroportin by hepcidin. However, the control of heart ferroportin protein by systemic hepcidin could apparently be overridden by changes in heart non-heme iron content since injection of ferric carboxymaltose to mice at 300 mg Fe/kg resulted in an increase in liver hepcidin expression, heart non-heme iron content, and also a threefold increase in heart ferroportin protein content. In a separate experiment, feeding an iron-deficient diet to young Wistar rats dramatically decreased liver hepcidin expression, while heart non-heme iron content and heart ferroportin protein content decreased to 50% of controls. It is, therefore, suggested that heart ferroportin protein is regulated primarily by the iron regulatory protein/iron-responsive element system and that the regulation of heart ferroportin by the hepcidin-ferroportin axis plays a secondary role.

1 November 2020 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LTL. Traeger
L. Traeger
JSJ. Schnittker
J. Schnittker
DDD.Y. Dogan
D.Y. Dogan
DOD. Oguama
D. Oguama
TKT. Kuhlmann
T. Kuhlmann
ASAndrea U Steinbicker
Andrea U Steinbicker

1 August 1996 in Innate Immunity
Verified
Journal Article
Closed access
JKJan Krijt
Jan Krijt
PMPavel Maruna
Pavel Maruna
PSPavla Stranska
Pavla Stranska
VJVaclav Janousek
Vaclav Janousek
Groups of 6 male BALB/c mice were treated twice daily for 4 days with 1000 mg/kg succinylacetone (SA), a heme biosynthesis inhibitor. Liver cytochrome P450 levels were slightly decreased and coumarin hydroxylase activity was increased from 124 ± 35 to 276 ± 37 pmol/mg/min. Renal cytochrome P450 content was decreased by SA treatment. SA had no effect on brain nitric oxide synthase activity. Administration of lipopolysaccharide (LPS) increased plasma nitrite/nitrate levels, and pretreatment with SA for 72 h partially attenuated this effect. Plasma nitrate levels were 305 ± 67 μmol/l in LPS-injected mice and 116 ± 27 μmol/l in LPS-injected, succinylacetone pretreated mice. These results indicate that succinylacetone treatment interferes with the inducible nitric oxide synthase activity or with its activation pathway.